19,008 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Rhumbline Advisers

Rhumbline Advisers bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,008 shares of the company’s stock, valued at approximately $331,000.

Several other hedge funds have also made changes to their positions in BCAX. RA Capital Management L.P. acquired a new position in Bicara Therapeutics in the third quarter valued at approximately $177,169,000. FMR LLC acquired a new position in shares of Bicara Therapeutics in the 3rd quarter valued at $57,913,000. Braidwell LP purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth $42,219,000. Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter worth about $30,329,000. Finally, Baker BROS. Advisors LP purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at about $21,225,000.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BCAX shares. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. HC Wainwright lifted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Bicara Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $41.20.

Bicara Therapeutics Stock Up 5.1 %

Shares of BCAX stock opened at $16.55 on Monday. Bicara Therapeutics Inc. has a fifty-two week low of $11.10 and a fifty-two week high of $28.09. The company has a 50 day simple moving average of $13.53.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.